Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) shares traded down 4.4% on Tuesday . The stock traded as low as $2.82 and last traded at $2.84, with a volume of 575,883 shares. The stock had previously closed at $2.97.

Separately, Maxim Group lowered their price target on shares of Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating on the stock in a research report on Thursday, July 21st.

The company’s 50 day moving average is $2.85 and its 200-day moving average is $5.22. The firm’s market cap is $60.40 million.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.